Galecto’s founders have pioneered the scientific exploration of galectin biology and chemistry.

Galectins represent a promising new drug-target. Galecto’s modulators may open up new treatment possibilities for many severe diseases.

Galectin-3 plays a key role in fibrosis development and Galecto’s inhibitors are able to potently block this effect, and may thus lend new hope to patients suffering from fibrosis.

Galecto, Inc. develops small molecules for the treatment of cancer and severe liver diseases. The company is built on nearly 15 years of research centering on the role of galectin-3 and the use of modulators of these proteins to treat cancer and severe liver diseases. These assets, combined with BRM-1420, a novel dual ENL-YEATS / FLT3 inhibitor, provide Galecto with a unique therapeutic platform.

Follow us

Board
Management
Founders